TD Cowen Upgrades Spero Therapeutics to Buy
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Ritu Baral has upgraded Spero Therapeutics (NASDAQ:SPRO) from Hold to Buy.
August 06, 2024 | 4:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen analyst Ritu Baral has upgraded Spero Therapeutics (NASDAQ:SPRO) from Hold to Buy.
An upgrade from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100